Vivus, Inc. (VVUSQ)
Stock Price Chart
Key Info
| Market Cap | 2.11M |
| Revenue (ttm) | 73.25M |
| Net Income (ttm) | -28.77M |
| Shares Out | 17.87M |
| EPS (ttm) | -2.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 1 |
| Last Price | $0.1180 |
| Previous Close | $0.1300 |
| Change ($) | -0.0120 |
| Change (%) | -9.23% |
| Day's Open | 0.1200 |
| Day's Range | 0.1180 - 0.1480 |
| Day's Volume | 64,898 |
| 52-Week Range | 0.07 - 3.57 |
More Stats
| Market Cap | 2.11M |
| Enterprise Value | 211.13M |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 17.87M |
| Float | n/a |
| EPS (basic) | -2.70 |
| EPS (diluted) | -2.70 |
| FCF / Share | -2.20 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 3.01M |
| Short Ratio | 3.45 |
| Short % of Float | n/a |
| Beta | -3.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 0.03 |
| PB Ratio | n/a |
| Revenue | 73.25M |
| Operating Income | -8.92M |
| Net Income | -28.77M |
| Free Cash Flow | -23.44M |
| Net Cash | -209.02M |
| Net Cash / Share | -11.70 |
| Gross Margin | 59.84% |
| Operating Margin | -12.18% |
| Profit Margin | -39.30% |
| FCF Margin | -32.00% |
| ROA | -2.20% |
| ROE | n/a |
| ROIC | -8.00% |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 69.76 | 65.06 | 65.37 | 124 | 95.43 | 114 | 81.08 | 2.01 | - | - |
| Revenue Growth | 7.22% | -0.48% | -47.39% | 30.21% | -16.42% | 40.82% | 3929.92% | - | - | - |
| Gross Profit | 54.09 | 50.45 | 48.73 | 114 | 61.27 | 80.79 | 76.21 | 1.83 | - | - |
| Operating Income | -10.97 | -3.48 | 2.79 | 55.69 | -60.28 | -50.71 | -155 | -140 | -47.08 | -65.63 |
| Net Income | -31.50 | -36.95 | -30.51 | 23.30 | -93.11 | -82.65 | -174 | -140 | -46.14 | -66.07 |
| Shares Outstanding | 10.64 | 10.62 | 10.57 | 10.44 | 10.39 | 10.35 | 10.12 | 9.83 | 8.44 | 8.10 |
| Earnings Per Share | -2.96 | -3.48 | -2.89 | 2.22 | -9.00 | -8.00 | -17.20 | -14.20 | -5.50 | -8.20 |
| Operating Cash Flow | -30.47 | -23.61 | -16.36 | 38.17 | -46.33 | -38.11 | -135 | -132 | -36.90 | -64.11 |
| Capital Expenditures | -0.04 | -0.03 | -0.02 | -0.21 | -0.31 | -0.26 | -1.80 | -1.67 | -0.20 | -0.11 |
| Free Cash Flow | -30.52 | -23.64 | -16.39 | 37.95 | -46.64 | -38.37 | -137 | -134 | -37.10 | -64.21 |
| Cash & Equivalents | 32.65 | 111 | 226 | 270 | 242 | 300 | 343 | 215 | 147 | 139 |
| Total Debt | 243 | 294 | 236 | 241 | 231 | 228 | 213 | - | - | - |
| Net Cash / Debt | -210 | -183 | -9.35 | 28.20 | 10.17 | 71.79 | 130 | 215 | 147 | 139 |
| Assets | 218 | 302 | 265 | 306 | 277 | 367 | 432 | 264 | 152 | 144 |
| Liabilities | 288 | 342 | 274 | 288 | 284 | 284 | 278 | 41.21 | 10.97 | 12.28 |
| Book Value | -69.22 | -40.02 | -9.34 | 18.19 | -7.09 | 82.52 | 153 | 223 | 141 | 132 |
Company Profile
Company Details
| Full Name | Vivus, Inc. |
| Country | United States |
| Employees | 59 |
| CEO | John P. Amos |
Stock Information
| Ticker Symbol | VVUSQ |
| Stock Exchange | US OTC |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | OTCMKTS: VVUSQ |
| IPO Date | April 6, 1994 |
Description
VIVUS operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California. On July 7, 2020, VIVUS, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.